en · de · es · fr · pt
sr9009-notes.peptides4088.com › Info › Background And Pharmacological Mechanism — Reference Sheet

Background And Pharmacological Mechanism — Reference Sheet

By Editorial Desk · published 2025-09-22 · last reviewed 2025-10-19 · Info

If you have been reading about SR9009 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2025-10-19. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Pharmacological Mechanism

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

Regulation, Testing, and Storage

Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.

SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.

Sr9009 at a glance

PropertyValueNotes
Molecular formulaC20H24ClN3O4SReported for the free base
Molecular weight437.9 g/molCalculated from the formula
Primary targetREV-ERBα and REV-ERBβNuclear receptors involved in circadian regulation
SolubilitySoluble in DMSO and ethanolPoorly soluble in water
Typical storage-20 °C, desiccatedProtect from light and moisture

SR9009 Background and Receptor Mechanism

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

Related pages on this site

Further detail

== Catabolism == Degradation of glycosphingolipids occurs in the lysosome, which contains digestive enzymes in animal cells. The lysosome breaks down the glycosphingolipid to its primary components, fatty acids, sphingosine, and saccharide.

A degron can be converted into its active form by a post-translational modification such as phosphorylation of a tyrosine, serine or threonine residue. In this case, the ubiquitin ligase exclusively recognizes the phosphorylated version of the substrate due to stabilization within the binding site. For example, FBW7, the F-box substrate recognition unit of an SCFFBW7ubiquitin ligase, stabilizes a phosphorylated substrate by hydrogen binding its arginine residues to the phosphate, as shown in the figure to the right. In absence of the phosphate, residues of FBW7 repel the substrate.

. This Laplacian term can be interpreted as the difference between the velocity at a point and the mean velocity in a small surrounding volume. This implies that – for a Newtonian fluid – viscosity operates as a diffusion of momentum, in much the same way as the heat conduction. In fact neglecting the convection term, incompressible Navier–Stokes equations lead to a vector diffusion equation (namely Stokes equations), but in general the convection term is present, so incompressible Navier–Stokes equations belong to the class of convection–diffusion equations. In the usual case of an external field being a conservative field:

== Other investments == In 2019, 777 Partners bought the London Lions, London's sole men's professional basketball team. They then invested £7 million for 45% of the British Basketball League (BBL). 777 sold a slight minority stake in the London Lions to O.G. Anunoby and became the first British team to ever qualify for EuroCup playoffs. In May 2024, British Basketball revoked the license of the operating company behind the BBL, due to concerns over its financing. The BBL folded and was replaced by Super League Basketball. In August 2024, administrators Hudson Weir allowed the London Lions to be sold to Tesonet, the creators of NordVPN and owners of Lithuanian team BC Žalgiris. The new owners defended their decision to keep Lenz Balan, former vice president of 777 Partners, as CEO of the Lions. In 2022, 777 invested in STX Entertainment, a global film studio known for producing films such as Molly's Game, The Irishman, and Ferrari.

=== Heart of stone === Severe forms of calciphylaxis may cause diastolic heart failure from cardiac calcification, called heart of stone. Widespread intravascular calcification typical of calciphylaxis lesions occur in the myocardium and prevent normal diastolic filling of the ventricles.

Sources: en.wikipedia.org

Supporting material

=== Mini-NAD-II Riboswitches === A NAD⁺-II class riboswitch, termed mini-NAD⁺-II, was first identified through iterative covariance model (CM) searches against representative bacterial genomes in the Genome Taxonomy Database. Mini-NAD⁺-II riboswitches lack the P1a stem and instead fold into a simple H-type pseudoknot, a compact RNA tertiary structure. The conserved nucleotides essential for tertiary contacts and specific recognition of the NMN moiety are retained, as is an A-rich tract following the P1 stem that likely forms a minor groove triplex. Mini-NAD⁺-II riboswitches lack the P1a stem and instead fold into a simple H-type pseudoknot, a compact RNA tertiary structure. The conserved nucleotides essential for tertiary contacts and specific recognition of the NMN moiety are retained, as is an A-rich tract following the P1 stem that likely forms a minor groove triplex. The potential for base pairing with the adjacent Shine–Dalgarno sequence is also retained, suggesting a conserved mechanism of translational regulation.

=== Medicinal applications === Human growth hormone (rHGH): Humatrope from Lilly and Serostim from Serono replaced cadaver harvested human growth hormone human insulin (BHI): Humulin from Lilly and Novolin from Novo Nordisk among others largely replaced bovine and porcine insulin for human therapy. Some prefer to continue using the animal-sourced preparations, as there is some evidence that synthetic insulin varieties are more likely to induce hypoglycemia unawareness. Remaining manufacturers of highly purified animal-sourced insulin include the U.K.'s Wockhardt Ltd. (headquartered in India), Argentina's Laboratorios Beta S.A., and China's Wanbang Biopharma Co. Follicle-stimulating hormone (FSH) as a recombinant gonadotropin preparation replaced Serono's Pergonal which was previously isolated from post-menopausal female urine Factor VIII: Kogenate from Bayer replaced blood harvested factor VIII

=== Liquid chromatography EI-MS === Two recent approaches for coupling capillary scale liquid chromatography-electron ionization mass spectrometry (LC-EI-MS) can be incorporated for the analysis of various samples. These are capillary-scale EI-based LC/MS interface and direct-EI interface. In the capillary EI the nebulizer has been optimized for linearity and sensitivity. The direct-EI interface is a miniaturized interface for nano- and micro-HPLC in which the interfacing process takes place in a suitably modified ion source. Higher sensitivity, linearity, and reproducibility can be obtained because the elution from the column is completely transferred into the ion source. Using these two interfaces electron ionization can be successfully incorporated for the analysis of small and medium-sized molecules with various polarities. The most common applications for these interfaces in LC-MS are environmental applications such as gradient separations of the pesticides, carbaryl, propanil, and chlorpropham using a reversed phase, and pharmaceutical applications such as separation of four anti-inflammatory drugs, diphenyldramine, amitriptyline, naproxen, and ibuprofen. Another method to categorize the applications of electron ionization is based on the separation technique which is used in mass spectroscopy. According to this category most of the time applications can be found in time of flight (TOF) or orthogonal TOF mass spectrometry (OA-TOF MS), Fourier transform ion cyclotron resonance (FT-ICR MS) and quadrupole or ion trap mass spectrometry.

== Preparation == The highly basic character of caricain makes it relatively easy to separate from the other papaya cysteine endopeptidases in cation-exchange chromatography of preparations of commercially available papaya latex. A sodium acetate gradient, pH 5.0, was first used successfully by Robinson and has since been adopted by others. Caricain is found in the latest-eluting protein peak. Due to the charge heterogeneity of caricain the peak may not be symmetrical, but this does not necessarily indicate the presence of contaminants. Covalent chromatography on thiol-Sepharose allows isolation of fully active caricain from the material obtained by cation exchange.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.

How does it work?

It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.

Is it proven to increase endurance in humans?

No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.

Is SR9009 legal?

Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.

Network